✦ LIBER ✦

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

✍ Scribed by Asselah, Tarik; Jensen, Donald M.; Foster, Graham; Sulkowski, Mark; Ouzan, Denis; Morano, Luis; Buynak, Robert; Agarwal, Kosh; Hassanein, Tarek; Forton, Daniel; Negro, Francesco; Genné, Daniel; Kaita, Kelly; Maieron, Andreas; Preotescu, Liliana; Sarrazin, Christoph; Zehnter, Elmar; Romero-Gomez, Manuel; Stern, Jerry O.; Quinson, Anne-Marie; Drulak, Murray; Garcia, Miguel; Voss, Florian; Böcher, Wulf; Ferenci, Peter

Book ID: 123028898
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 233 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)63551-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P723 FALDAPREVIR PLUS PEGYLATED INTERFER

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

✍ Asselah, T.; Jensen, D.M.; Foster, G.R.; Sulkowski, M.S.; Ouzan, D.; Morano, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Su1056 Effect of HCV Genotype-1 Subtype

Su1056 Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Pooled Data From Phase III Trials

✍ Jacobson, Ira M.; Jensen, Donald M.; Dieterich, Douglas T.; Sarrazin, Christoph; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Su1053 Virological Response in Treatment

Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

✍ Asselah, Tarik; Jensen, Donald M.; Foster, Graham; Sulkowski, Mark; Ouzan, Denis 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 1018 KB

Su1058 Early Stopping Rules for Faldapre

Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Exploratory Study of Pooled Data From Phase III Trials

✍ Ferenci, Peter; Dieterich, Douglas T.; Zeuzem, Stefan; Mantry, Parvez S.; Sarraz 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 233 KB

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE O

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS

✍ Jacobson, I.M.; Jensen, D.M.; Dieterich, D.; Sarrazin, C.; Foster, G.R.; Yoshida 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Su1054 Ns3 Q80k Did Not Impact Efficacy

Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribavirin in Three Phase III Trials

✍ Berger, Kristi; Sarrazin, Christoph; Ferenci, Peter; Jensen, Donald M.; Jacobson 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 396 KB